Clontarf’s lithium-magnesium breakthrough: why this update matters now
Clontarf Energy’s interim statement is short on revenue, but big on ambition. The company says recent lab and pilot-plant work has cracked a key bottleneck in brine processing: extracting 100% of the magnesium. That sounds niche, but it could be pivotal. If proven at scale, Clontarf believes it opens two revenue streams from the same brine – lithium and magnesium – and may make salares (salt flats) that were previously uneconomic worth developing.
The technical work is being done with JV partner NEXT-ChemX at an industrial site in India. Early results from samples sourced via YLB and synthetic brines are described as “highly encouraging”, including runs based on Uyuni chemistries. Management now feels confident enough to plan larger-scale plants once the legal and commercial pieces are in place.
On the commercial side, Clontarf reports strong interest in long-term offtake contracts for high-purity lithium and magnesium at prices above current spot. That’s a notable claim, if it can be converted into binding contracts.
Direct Lithium Extraction (DLE) in plain English
DLE refers to technologies that pull lithium directly from brines using selective media or solvents, rather than relying on vast evaporation ponds. The prize is faster throughput, higher purities, and less water and land use. Clontarf highlights that its process does not use significant volumes of fresh water, nor high electricity use or toxic chemicals.
Magnesium is usually a headache in brines because it can contaminate lithium streams. If Clontarf’s approach truly removes and monetises magnesium, overall project economics may improve in Bolivia and potentially in other countries with challenging brine chemistries.
Roadmap: samples, pilot, and a staged rollout
Next steps are practical. Clontarf has sourced IBCs to ship larger bulk samples to Mumbai for expedited processing. The company expects arrival at the Indian plant about two months after export. These larger runs should refine recovery and throughput not only for lithium but also for magnesium and any other economic minerals.
Assuming positive results, Clontarf intends to negotiate agreements and aims to deploy a 500 tonnes per year pilot plant to a Bolivian salar, targeting arrival by mid-2026. Longer term, it plans to expand to five separate salares, adding a new plant every six months, initially at the 500 t/y scale, all subject to permitting and local restrictions.
The headline ambition is bold: 150,000 tonnes of lithium carbonate equivalent (LCE) by 2030. That is a step-change from today’s position and will require flawless execution on technology, permitting, funding, offtake and logistics.
Bolivia’s policy backdrop could be turning
Clontarf points to shifting global policy on critical minerals, citing the US Inflation Reduction Act and the EU’s Critical Resource Minerals Act. Notably, it says EU Global Gateway funds can provide 20-year financing at around 3% for state-allocated infrastructure that supports new operations – potentially covering two-thirds of capex while respecting Bolivian sovereignty.
At home in Bolivia, recent elections are said to signal more pro-business policies. If confirmed in the October 2025 second round, reforms to the Lithium Law – and even the Hydrocarbon Law – could accelerate. For Clontarf, faster licensing, clearer titles, and acceptance of proven DLE technologies are the gatekeepers to progress.
Financial snapshot: lean cost base, modest cash burn
These are unaudited numbers for the six months to 30 June 2025. Clontarf is still pre-revenue and posted a small loss with tight operating costs. Cash dipped as the company funded ongoing work without raising new equity during the half.
| Metric | H1 2025 |
|---|---|
| Administrative expenses | £158,000 |
| Impairment (exploration & evaluation) | £87,000 |
| Loss before tax | £245,000 |
| Loss per share | 0.003p |
| Cash and cash equivalents (30 June 2025) | £579,000 |
| Operating cash outflow | £239,000 |
| Total assets | £1.94 million |
| Total liabilities | £1.36 million |
| Total equity | £584,000 |
| Intangible assets | £434,000 |
| Investment in JV | £888,000 |
| Shares in issue (average) | 8,193,326,117 |
There is no dividend. Net cash used in operations was £239,000, and period-end cash stood at £579,000. The balance sheet shows £888,000 invested in the NEXT-ChemX JV and intangibles of £434,000 after a further £87,000 impairment mainly related to Ghana’s Tano 2A Block, which still awaits government ratification.
My read: the cash burn is modest, but scaling to field units and multiple salares will require significant capital. Management prefers non-dilutive funding via offtakers and EU-related infrastructure finance; whether that fully replaces equity remains to be seen.
NEXT-ChemX JV: terms and where things stand
Clontarf’s 50:50 JV with NEXT-ChemX covers marketing, testing and deployment of NCX’s DLE technology in Bolivia. Clontarf has already paid US$500,000 and issued 385 million shares to NCX. Further share issuances are contingent on milestones: successful pilot processing of Bolivian brines and then a construction/processing contract with Bolivian authorities.
As at 30 June 2025, no trading activity has begun in the JV, so there are no JV revenues or costs yet. The pilot plant in India is the key proving ground. Warrants granted in 2022 expired in January 2025; there were no new share issues in H1 2025.
What could move the share price next
- Revised Memorandum of Understanding being completed and implemented.
- Export and processing of larger Bolivian bulk brine samples in India, including magnesium runs.
- Independent validation of lithium and magnesium purities, recoveries and throughput.
- Site visits by Bolivian authorities to the pilot plant and sign-off on detailed engineering.
- First binding offtake agreements, especially if priced above spot as suggested.
- Clarity on Bolivia’s second-round election outcome and possible reform of the Lithium Law.
- Funding news: offtaker prepayments or EU-backed infrastructure finance versus equity raises.
Risks to keep in view
- Scale-up risk: translating pilot success into commercial plants is rarely linear.
- Permitting and political risk in Bolivia; timelines depend on national policy and YLB processes.
- Technology risk: DLE performance must be proven on real brines at volume and over time.
- Funding risk: mid- to large-scale rollout will likely require substantial capital.
- Asset risk outside Bolivia: the Ghana Tano 2A Block still awaits ratification and has seen impairments.
My take: promise building, proof pending
This update is encouraging on the science and the strategy. If Clontarf has genuinely turned magnesium from a contaminant into a co-product, economics across certain brines could improve materially. Policy tailwinds and potential EU-backed financing are helpful, and reported offtake interest – at above-spot pricing – suggests end-user appetite for clean, reliable supply.
But we’re still pre-revenue, and the JV has yet to transact commercially. The immediate milestones are shipping bulk samples, running larger campaigns in India, and converting that data into Bolivian approvals and offtakes. With £579,000 in cash and a modest cost base, Clontarf has some room to manoeuvre, but meaningful scale-up will need fresh capital one way or another.
Overall, this is a story with increasing technical credibility and significant optionality, now hinging on execution and policy follow-through in Bolivia. For investors, the next few quarters should reveal whether the magnesium breakthrough can graduate from promising test results to bankable contracts.
